Immunisation with BCG and recombinant MVA85A induces long-lasting, polyfunctional Mycobacterium tuberculosis-specific CD4+ memory T lymphocyte populations.
about
Enumeration of functional T-cell subsets by fluorescence-immunospot defines signatures of pathogen burden in tuberculosisImmune mechanisms of protection: can adjuvants rise to the challenge?Tuberculosis vaccines: beyond bacille Calmette-GuerinSafety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South AfricaPeptide microarray-based identification of Mycobacterium tuberculosis epitope binding to HLA-DRB1*0101, DRB1*1501, and DRB1*0401Measuring Cellular Immunity to Influenza: Methods of Detection, Applications and ChallengesFunctional Signatures of Human CD4 and CD8 T Cell Responses to Mycobacterium tuberculosisPrime-boost approaches to tuberculosis vaccine developmentVariability in tuberculosis granuloma T cell responses exists, but a balance of pro- and anti-inflammatory cytokines is associated with sterilizationHypoxia induces an immunodominant target of tuberculosis specific T cells absent from common BCG vaccinesA subset of circulating blood mycobacteria-specific CD4 T cells can predict the time to Mycobacterium tuberculosis sputum culture conversionStrategic Priming with Multiple Antigens can Yield Memory Cell Phenotypes Optimized for Infection with Mycobacterium tuberculosis: A Computational StudySerum indoleamine 2,3-dioxygenase activity is associated with reduced immunogenicity following vaccination with MVA85AEffect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adultsSignatures of T cells as correlates of immunity to Francisella tularensisA Phase I study evaluating the safety and immunogenicity of MVA85A, a candidate TB vaccine, in HIV-infected adultsA Subset of Protective γ9δ2 T Cells Is Activated by Novel Mycobacterial Glycolipid ComponentsEstablishment of an aerosol challenge model of tuberculosis in rhesus macaques and an evaluation of endpoints for vaccine testingNovel vaccination strategies against tuberculosis.The duration of antigen-stimulation significantly alters the diversity of multifunctional CD4 T cells measured by intracellular cytokine stainingNatural variation in immune responses to neonatal Mycobacterium bovis Bacillus Calmette-Guerin (BCG) Vaccination in a Cohort of Gambian infants.MVA.85A boosting of BCG and an attenuated, phoP deficient M. tuberculosis vaccine both show protective efficacy against tuberculosis in rhesus macaques.Safety and immunogenicity of boosting BCG vaccinated subjects with BCG: comparison with boosting with a new TB vaccine, MVA85AAutocrine production of beta-chemokines protects CMV-Specific CD4 T cells from HIV infectionImmunological memory transferred with CD4 T cells specific for tuberculosis antigens Ag85B-TB10.4: persisting antigen enhances protection.Polyfunctional T lymphocytes are in the peripheral blood of donors naturally immune to coccidioidomycosis and are not induced by dendritic cells.Prime-boost immunization with adenoviral and modified vaccinia virus Ankara vectors enhances the durability and polyfunctionality of protective malaria CD8+ T-cell responsesProtection against Chlamydia promoted by a subunit vaccine (CTH1) compared with a primary intranasal infection in a mouse genital challenge model.Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal deliveryExpanded polyfunctional T cell response to mycobacterial antigens in TB disease and contraction post-treatmentMycobacterium tuberculosis PPD-induced immune biomarkers measurable in vitro following BCG vaccination of UK adolescents by multiplex bead array and intracellular cytokine staining.HIV-1 infection in infants severely impairs the immune response induced by Bacille Calmette-Guérin vaccine.The effect of current Schistosoma mansoni infection on the immunogenicity of a candidate TB vaccine, MVA85A, in BCG-vaccinated adolescents: An open-label trial.The next 10 years for tuberculosis vaccines: do we have the right plans in place?Recognition and killing of autologous, primary glioblastoma tumor cells by human cytomegalovirus pp65-specific cytotoxic T cells.Polyfunctional T-cell responses are disrupted by the ovarian cancer ascites environment and only partially restored by clinically relevant cytokines.Incomplete recovery of pneumococcal CD4 T cell immunity after initiation of antiretroviral therapy in HIV-infected malawian adults.Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in Mycobacterium tuberculosis-infected individuals.The personal touch: strategies toward personalized vaccines and predicting immune responses to them.Highly persistent and effective prime/boost regimens against tuberculosis that use a multivalent modified vaccine virus Ankara-based tuberculosis vaccine with interleukin-15 as a molecular adjuvant.
P2860
Q21135592-B748BE61-82D8-4C46-B6A7-F020A8C106ECQ21245319-3A24353A-623F-4349-BC20-6C1710AF2EA8Q22242669-09BDB2CD-E744-4398-AD46-18C80747AC35Q24647137-596A57C4-A6FF-448A-A94F-A5A9A63A4579Q24656969-BA44CDCE-A710-4534-8569-5920FE19899BQ26783884-0DA81C00-808A-428F-B21B-EB5AE09639D8Q26849399-2ACBDCD6-8B80-4756-8BBB-DB38E1BB9FEFQ27024526-704E3F90-1478-42A4-B59C-F1788B73EFBDQ27321593-6CE20CEE-8609-490F-8E66-608992CF9E50Q28476626-89847BFD-61C0-4C01-94E8-A125E5A9CB2AQ28541001-32BFFA10-217C-4898-8E57-F4C372F5368EQ28603191-79C59888-383D-4B5E-868B-9A4B1F26333CQ28649845-6F2CA6DC-805A-4D0A-90F1-52F4B31B211DQ28728311-ED701D44-0C0C-4D95-BC2C-D44CF9B33FD7Q28731483-45E1C42D-FA76-4FDA-A44E-9B88099DED72Q28742450-402C6511-0178-4171-8959-518B74296C7DQ28829233-928C16F3-19A6-40B6-9B1C-C62F0AD523D5Q30227121-3D337C53-6301-4975-8725-2A2E8C167573Q30363188-E0298DFD-740C-4A0C-814C-CB4505F4CB8BQ31068532-933D9DAD-46A4-41EE-BF7E-5E0E51822701Q33378483-388392EA-CAD3-42D9-A0A1-CBBD819421B1Q33430265-0FECBCDD-4CEB-49D8-AA15-7999214A22EBQ33468451-C7883D78-5B87-48CF-8572-AA5771C3716FQ33513965-B3E22506-96EC-4D5C-B472-EEC474D8977FQ33518560-5C06C08B-840E-4160-B7CC-AC24FB4233E2Q33557707-A08EBE3B-5E36-4157-9F3B-710551E2831AQ33557760-CA46F469-0B18-4217-9C38-A6DF33F9F5B5Q33588632-27A03304-5500-4189-BB20-74247B93A980Q33603206-F34ED187-E158-4055-A3B3-F2305428C4BCQ33614724-4C587E31-D190-4FC0-99CB-76CDF64975FEQ33626980-26635C3F-0EE0-45AB-9891-E1B7725C61B2Q33627000-0694B11F-BB82-42EA-A8FA-EED16FD28A1FQ33637297-9E4EE1F8-9FE5-4274-9322-18B8ABDBCE6DQ33659150-E292BF35-254F-400F-B511-20A82DDE6620Q33761585-B36CD6F8-2C28-4A32-AAA9-390539FA473CQ33784707-140BE636-B575-41A7-BAB9-BA6BFCE0C54FQ33800556-1E74246E-1083-4B9D-98E1-EE19BA04178BQ33807147-75D2281A-16F8-4D35-8B75-2956745F8E4CQ33813977-C2B45500-F60D-44FB-B065-0721FF698435Q33825708-633A39DC-F2DA-4702-965D-BD06D764165D
P2860
Immunisation with BCG and recombinant MVA85A induces long-lasting, polyfunctional Mycobacterium tuberculosis-specific CD4+ memory T lymphocyte populations.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Immunisation with BCG and reco ...... mory T lymphocyte populations.
@ast
Immunisation with BCG and reco ...... mory T lymphocyte populations.
@en
type
label
Immunisation with BCG and reco ...... mory T lymphocyte populations.
@ast
Immunisation with BCG and reco ...... mory T lymphocyte populations.
@en
prefLabel
Immunisation with BCG and reco ...... mory T lymphocyte populations.
@ast
Immunisation with BCG and reco ...... mory T lymphocyte populations.
@en
P2093
P2860
P50
P356
P1476
Immunisation with BCG and reco ...... mory T lymphocyte populations.
@en
P2093
Ansar A Pathan
Clare R Sander
Daniel C Douek
David R Ambrozak
Joseph P Casazza
Mario Roederer
Melissa L Precopio
Natalie E R Beveridge
Nicola C Alder
Richard A Koup
P2860
P304
P356
10.1002/EJI.200737504
P407
P577
2007-11-01T00:00:00Z